Literature DB >> 19380190

Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma.

Tao Zhang1, Jingcun Zheng, Ning Jiang, Guozeng Wang, Quan Shi, Chunfang Liu, Yuan Lu.   

Abstract

The lack of effective anti-tumor therapy for renal cell carcinoma (RCC) has stimulated the search for novel target whose inhibition could block tumorigenesis. Recently, reduced DLC-1 has been shown to be associated with aggressive and highly metastatic renal cell carcinoma. In this study, the biological role of DLC-1 on cell growth, migration and cell cycle progression in RCC cells was investigated. Over-expression of DLC-1 was associated with a marked inhibition of cell growth (P<0.01). The inhibitory effect was partly due to the induction of apoptosis and cell cycle arrest in G(0)/G(1) accompanied by up-regulation of the intracellular signal proteins of p27 and down-regulation of cyclin D1 and cyclin E. Furthermore, DLC-1 induced FAK dephosphorylation of focal adhesion proteins inhibited cell migration (P<0.05). Decreased DLC-1 expression strongly correlated with proliferative activity, as indicated by the elevated levels of Ki67. Restoration of DLC-1 expression in RCC cells led to Bcl-2 and caspase-3 mediated apoptosis as well as attenuated the ability of the cells to form RCC tumors in athymic nude mice (P<0.05). Taken together, these results suggest that DLC-1 plays a crucial role in signal transduction pathway regulating the cell proliferation, migration, and carcinogenesis of human RCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380190     DOI: 10.1016/j.canlet.2009.03.025

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells.

Authors:  Yi-Ping Shih; Yoshikazu Takada; Su Hao Lo
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

2.  DLC1 as a regulator of proliferation, invasion, cell cycle, and apoptosis in cutaneous squamous cell carcinoma.

Authors:  Cailing Yang; Dapeng Wu; Jinling Jia; Dong Liu; Zhanguo Li; Chunxiao Zhang; Min Li; Yonghua Xia
Journal:  Tumour Biol       Date:  2013-04-28

3.  Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.

Authors:  Archna Ravi; Shelly Kaushik; Aarthi Ravichandran; Catherine Qiurong Pan; Boon Chuan Low
Journal:  J Biol Chem       Date:  2014-12-18       Impact factor: 5.157

4.  DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells.

Authors:  Minhua Feng; Bo Huang; Zunguo Du; Xiaoping Xu; Zi Chen
Journal:  Mol Biol Rep       Date:  2010-10-01       Impact factor: 2.316

5.  DLC-1 induces mitochondrial apoptosis and epithelial mesenchymal transition arrest in nasopharyngeal carcinoma by targeting EGFR/Akt/NF-κB pathway.

Authors:  Wei Huang; Jie Liu; Xiangling Feng; Huan Chen; Liang Zeng; Guoling Huang; Weidong Liu; Lei Wang; Wei Jia; Jiawen Chen; Caiping Ren
Journal:  Med Oncol       Date:  2015-03-17       Impact factor: 3.064

6.  Detection and Clinical Significance of DLC1 Gene Methylation in Serum DNA from Colorectal Cancer Patients.

Authors:  Ping-Ping Wu; Ji-Hong Zou; Ri-Ning Tang; Yao Yao; Cheng-Zhong You
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

7.  DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.

Authors:  Yu-Zheng Xue; Tie-Long Wu; Yan-Min Wu; Ying-Yue Sheng; Zhe-Qiang Wei; Yu-Feng Lu; Li-Hua Yu; Jian-Ping Li; Zhao-Shen Li
Journal:  Tumour Biol       Date:  2013-05-17

8.  Frequent Downregulation and Promoter Hypermethylation of DLC1: Relationship with Clinical Outcome in Gallbladder Cancer.

Authors:  Deepika Singh; Amisha Bharti; Dipanjan Biswas; Mallika Tewari; Amrita Ghosh Kar; Mumtaz Ahmed Ansari; Sunita Singh; Gopeshwar Narayan
Journal:  J Gastrointest Cancer       Date:  2021-01-08

9.  Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.

Authors:  Eva Juengel; Dana Kim; Jasmina Makarević; Michael Reiter; Igor Tsaur; Georg Bartsch; Axel Haferkamp; Roman A Blaheta
Journal:  J Cell Mol Med       Date:  2014-12-02       Impact factor: 5.310

10.  Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.

Authors:  Yuqi Su; Li Lin; Jingwen Zhang; Yaqi Jiang; Changqie Pan; Li Sun; Jiangman Duan; Wangjun Liao
Journal:  Mol Med Rep       Date:  2015-08-03       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.